Abstract

ObjectiveThis Phase 2 study assessed the performance of positron emission tomography (PET) brain images made with Flutemetamol F 18 Injection in detecting β-amyloid neuritic plaques in Japanese subjects.MethodsSeventy subjects (25 with probable Alzheimer’s disease (pAD), 20 with amnestic mild cognitive impairment (aMCI), and 25 cognitively normal healthy volunteers[HVs]) underwent PET brain imaging after intravenous Flutemetamol F 18 Injection (185 MBq). Images were interpreted as normal or abnormal for neuritic plaque density by each of five non-Japanese and five Japanese readers who were blinded to clinical data. The primary efficacy analysis (based on HV and pAD data) was the agreement of the non-Japanese readers’ image interpretations with the clinical diagnosis, resulting in estimates of positive percent agreement (PPA; based on AD subjects; similar to sensitivity) and negative percent agreement (NPA; based on HVs; similar to specificity). Secondary analyses included PPA and NPA for the Japanese readers; inter-reader agreement (IRA); intra-reader reproducibility (IRR); quantitative image interpretations (standardized uptake value ratios [SUVRs]) by diagnostic subgroup; test–retest variability in five pAD subjects; and safety.ResultsPPA was 92% for all non-Japanese readers and ranged from 88 to 92% for the Japanese readers. NPA ranged from 96 to 100% for both the non-Japanese readers and the Japanese readers. The majority image interpretations (the interpretations made independently by ≥3 of 5 readers) resulted in PPA values of 92 and 92% and NPA values of 100 and 96% for the non-Japanese and Japanese readers, respectively. IRA and IRR were strong. Composite SUVR values (mean of multiple regional values) allowed clear differentiation between pAD subjects and HVs. Test–retest variability ranged from 1.14 to 2.27%, and test–retest agreement of the blinded visual interpretations was 100% for all readers. Flutemetamol F 18 Injection was generally well tolerated.ConclusionsThe detection of brain neuritic plaques in Japanese subjects using [18F]Flutemetamol PET images gave results highly consistent with clinical diagnosis, with non-Japanese and Japanese readers giving similar results. Inter-reader agreement and intra-reader reproducibility were high for both sets of readers. Visual delineation of abnormal and normal scans was corroborated by quantitative assessment, with low test–retest variability.Trial registrationClinicaltrials.gov registration number NCT02813070.

Highlights

  • The rapid growth of the aged population in Japan [1] poses medical and economic challenges because of ageassociated diseases such as dementia, of which the prevalence increased significantly from 1985 to 2005 [2]

  • The primary objective of this study was to assess the performance of Flutemetamol F 18 Injection in Japanese subjects as indicated by the level of agreement with clinical diagnosis of the blinded visual interpretations of ­[18F] flutemetamol brain images made by the non-Japanese readers

  • Among the non-Japanese readers, positive percent agreement (PPA) was 92% for all readers and negative percent agreement (NPA) ranged from 96% to 100%

Read more

Summary

Introduction

The rapid growth of the aged population in Japan [1] poses medical and economic challenges because of ageassociated diseases such as dementia, of which the prevalence increased significantly from 1985 to 2005 [2]. Alzheimer’s disease (AD) is the predominant type of dementia in the Japanese population, [1, 2] with an incidence rate comparable to that of Western populations [3]. The presence of amyloid plaques in the brain is one of the microscopic hallmarks of AD. While the presence of amyloid plaques is necessary but not sufficient for a pathological diagnosis of AD, an absence of plaques excludes AD. A definitive diagnosis of AD requires microscopic examination of brain tissue obtained at biopsy or autopsy, [4] recently approved amyloid-specific positron emission tomography (PET) radiotracers may facilitate

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.